Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The SURMOUNT-5 trial confirmed tirzepatides superiority over semaglutide in levels of weight loss [6]
Daily GLP-1 support supplement formulated to complement weight loss medications
The current evidence base justifies a proactive, complication-oriented deployment of pharmacotherapy to reduce long-term obesity burden and improve quality-adjusted survival across diverse populations
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
And in the weight loss market, their testimonials can have a huge impact, considering 40% of US adults are considered obese
Long-Term Treatment Strategies Some patients use GLP-1 therapy as a short-term intervention: lose weight over 612 months, then stop while maintaining new eating and exercise habits
US$ 24.77
US$ 26.76
US$ 29.21
US$ 27.75
US$ 20.40
US$ 22.97
US$ 27.32
US$ 26.31
US$ 24.29
US$ 28.66
US$ 29.14
US$ 42500.00
Sold : Login>>